The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTI1.L Regulatory News (TI1)

  • There is currently no data for TI1

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Compulsory Share Redemption by 30 June 2023

2 Sep 2022 07:00

RNS Number : 0284Y
Trian Investors 1 Limited
02 September 2022
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 which forms part of domestic law in the United Kingdom pursuant to The European Union (Withdrawal) Act 2018, as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019

 

TRIAN INVESTORS 1 LIMITED(the "Company")

 

Compulsory Share Redemption by 30 June 2023

 

 

2 September 2022

 

 

Following the Extraordinary General Meeting held on 5 August 2022 the Board has been working with Trian Investors Management, LLC (the "Investment Manager") and the Company's advisers to formulate proposals to achieve the objectives of shareholders as a whole (the "Proposals").

 

The Board notes that the Company's holdings in Ferguson plc ("FERG") and Unilever plc ("ULVR") which are held through Trian Investors I, L.P. (the "Investment Partnership") have significantly outperformed the FTSE 100 over relevant periods. In its recent discussions with the Board, the Investment Manager has reiterated that it is very pleased with the FERG and ULVR investments to date and believes that there is still significant value potentially to be achieved through the Company's holdings in FERG and ULVR. Nevertheless, the Board acknowledges that a significant portion of the current shareholder base would like the opportunity to exit their shareholding at or around net asset value.

 

Following consultation with major shareholders, the Board announces that the Company will, by no later than 30 June 2023, compulsorily redeem no less than 95 per cent. of each shareholders' holding in the Company, such redemption to be satisfied by a distribution of the Investment Partnership's underlying assets (including an in specie distribution of shares) at a value equivalent to the Board's estimate of the then prevailing net asset value (the "Redemption")[1].

 

The Board believes that the Redemption will have the following benefits:

 

The Redemption represents a significant return of capital to shareholders. For illustrative purposes only, if the Redemption had occurred on 31 July 2022, based on the NAV per share as at close of business on 31 July 2022, and specifically the closing prices of FERG and ULVR shares on such date, it is estimated that the Redemption would have returned approximately £420 million of value to shareholders;

 

The current discount of holding FERG and ULVR shares through the Company will be eliminated in respect of those assets that are distributed in-specie to shareholders;

 

The Redemption will allow each shareholder to determine the most opportune time to realise their exposure to ULVR and/or FERG (and, in the case of FERG, taking into consideration its potential eligibility for inclusion in various U.S stock indices, including the S&P 500 Index);

 

The traded market in FERG and ULVR shares is significantly more liquid when compared to trading in the Company's shares.

 

Details of the Redemption will be announced in due course. Once the Redemption has been completed the Board will commence a process to wind-up the Company with any residual net assets to be returned to shareholders in cash through that process.

 

As part of the Proposals and conditional on their successful implementation, it has been agreed: (a) with the Investment Manager that on Redemption it will receive its final Management Fee payment in lieu of notice calculated, through to 31 December 2023; (b) with Trian Investors 1 SLP, L.P. (the "Special Limited Partner") that it will continue to be entitled to receive the Incentive Allocation which will be determined based on the performance of the Investment Partnership at or about the time of Redemption, i.e., on or before 30 June 2023; and (c) with the Special Limited Partner that its Incentive Allocation may (at the Special Limited Partner's election) be settled through an in-specie distribution of the Investment Partnership's underlying assets rather than in cash or through a further issue of the Company's shares.

 

Shareholders (including Trian Subscriber) representing approximately 86.3 per cent. of the issued share capital have indicated their support for the Proposals as a whole (including the Redemption and subsequent winding-up of the Company).

 

Mark Thompson, Chairman of the Company, commented: "The Board is confident that its proposals represent a positive and sensible way forward that delivers an outcome which all shareholders can support. The share redemption scheme recognises the significant potential future upside from the Company's core holdings, while meeting the desire of certain investors for greater liquidity and of the Company's Board to see its discount to fair value unwind."

 

 

LEI: 213800UQPHIQI5SPNG39

 

Terms not defined in this announcement shall have the meaning defined in the Company's prospectus dated 21 September 2018.

 

For further information, please contact:

 

Numis Securities Limited

(Joint corporate broker) 

+44 (0)20 7260 1000

David Benda

Nathan Brown

Vicki Paine

 

Jefferies International Limited

(Joint corporate broker)

+44 (0)20 7029 8000

Stuart Klein

 

Greenbrook

(Communications Adviser)

+44 (0)20 7952 2000

Andrew Honnor

Rob White

Bree Taylor

 

Ocorian Administration (Guernsey) Limited(Administrator and Company Secretary)+44 (0)1481 742 742Chezi Hanford

 

 

 


[1] Subject to compliance with any restrictions on dealings in the ULVR or FERG shares under any applicable laws and regulations

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSFEFFEESEFU
Date   Source Headline
26th Apr 20234:22 pmRNSNotice of EGM Results
26th Apr 20234:21 pmRNSNotice of AGM Results
26th Apr 20237:30 amRNSSuspension - Trian Investors 1 Limited
17th Apr 20235:03 pmRNSNet Asset Value as at 31 March 2023
6th Apr 20232:55 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSTotal Voting Rights
24th Mar 20237:01 amRNSNotice of EGM
24th Mar 20237:00 amRNSNotice of AGM
22nd Mar 20237:00 amRNSDirector/PDMR Shareholding
17th Mar 20237:00 amRNSAnnual Report to 31 December 2022
16th Mar 202312:08 pmRNSNAV as at 28 February 2023 and as at 13 March 2023
14th Mar 20232:43 pmRNSTotal Voting Rights
2nd Mar 20237:00 amRNSCompulsory Share Redemption Update
22nd Feb 20232:53 pmRNSNet Asset Value as at 16 February 2023
22nd Feb 20232:37 pmRNSNet Asset Value as at 31 January 2023
17th Feb 20237:00 amRNSCompulsory Share Redemption Update
1st Feb 20237:00 amRNSTotal Voting Rights
19th Jan 20237:00 amRNSIn-specie Distribution & Complusory Redemption
19th Jan 20237:00 amRNSNet Asset Value as at 6 January 2023
9th Jan 20236:01 pmRNSNet Asset Value as at 31 December 2022
9th Jan 20237:00 amRNSCompulsory Share Redemption Update
14th Dec 20225:26 pmRNSNet Asset Value as at 30 November 2022
11th Nov 20224:34 pmRNSNet Asset Value as at 31 October 2022
26th Oct 20225:16 pmRNSReplacement - Net Asset Value(s)
25th Oct 20224:16 pmRNSNet Asset Value as at 30 September 2022
24th Oct 20228:51 amRNSHolding(s) in Company
15th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSNet Asset Value as at 31 August 2022
6th Sep 202210:42 amRNSHolding(s) in Company
2nd Sep 20227:00 amRNSCompulsory Share Redemption by 30 June 2023
15th Aug 20225:30 pmRNSChanges to Director Roles and Responsibilities
12th Aug 20227:00 amRNSNet Asset Value as at 31 July 2022
8th Aug 20227:00 amRNSResult of EGM
8th Aug 20227:00 amRNSDirector Changes
8th Aug 20227:00 amRNSResult of AGM
11th Jul 20222:01 pmRNSNotice of AGM
11th Jul 20222:00 pmRNSNotice of Requisitioned EGM
11th Jul 20227:00 amRNSNet Asset Value as at 30 June 2022
1st Jul 20227:00 amRNSTotal Voting Rights
21st Jun 20227:00 amRNSTransaction in Own Shares
20th Jun 20223:56 pmRNSReceipt of Requisition Notice
15th Jun 20227:00 amRNSNet Asset Value as at 31 May 2022
31st May 20228:00 amRNSInvestment in Unilever
6th May 20226:00 pmRNSNet Asset Value as at 30 April 2022
14th Apr 20227:01 amRNSDirector Appointment
14th Apr 20227:00 amRNSAnnual Report to 31 December 2021
13th Apr 20225:53 pmRNSNet Asset Value as at 31 March 2022
29th Mar 202210:11 amRNSNew US$100m Revolving Credit Facility
16th Mar 20224:53 pmRNSNet Asset Value as at 28 February 2022
1st Mar 20227:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.